NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Biotechnology · USD

Nuvation Bio Inc. (NUVB) Stock Analysis

Nuvation Bio Inc. (NUVB) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

NUVB

$6.81

+$0.04 (+0.59%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NUVB with… →

NUVB Key Statistics

As of Sep 4, 2026
Trading
Open
$6.78
Previous Close
$6.77
Day's Range
6.72–6.87
52-Week Range
2.99–9.75
Volume
3.76M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
$2.39B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.07
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.44
Financials (FY)
Revenue (FY)
$62.90M+698.96%
Net Income (FY)
−$204.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
−88.19%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
350.12M
1-Year Return
+99.12%
Dividend and dates
Earnings Date
November 2, 2026
Avg Volume
6.83M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NUVB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.00%
2025+236.84%
2024+76.16%
2023−21.35%
2022−77.41%
2021−27.35%
2020 (partial year)+20.62%

As of September 4, 2026.

NUVB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$62.90M−$204.63M−325.3%
2024$7.87M−$567.94M−7213.8%
2023$0.00−$75.80M—
2022$0.00−$104.20M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$62.90M$53.60M−$213.06M−$204.63M−325.3%
2024$7.87M$795.00K−$167.56M−$567.94M−7213.8%
2023$0.00$0.00−$99.82M−$75.80M—
2022$0.00—−$119.73M−$104.20M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NUVB Valuation vs Biotechnology Median

Median of 656 stocks
MetricNUVBBiotechnology medianvs median
P/S ratio14.0715.268% below
Profit margin−88.19%0.00%88.2 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Nuvation Bio Inc. (NUVB) carries a market capitalisation of $2.39B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 305 employees.

Over the past 52 weeks the price has ranged from $2.99 to $9.75. NUVB last closed at $6.81 on September 4, 2026. That is +$0.04 (+0.59%) against the previous close. The latest close sits 127.76% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $62.90M. That is +698.96% against the prior fiscal year, when revenue was $7.87M. The same year closed with a net loss of $204.63M. Profit margin runs at −88.19%. That is 88.2 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.44.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $62.90M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 14.07. On price-to-sales that is 7.79% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +99.12%. Measured over 5 years, that is −7.21% a year compounded. Beta against the wider market is reported at 1.53. Annualized volatility over the trailing 6 years is 72.77%.

Growth & Income

The record shows no dividend for NUVB.

Across the complete calendar years on file, 2025 returned +236.84% and 2022 returned −77.41%. Of the 5 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −24.00% year to date.

Peer Comparison

Nuvation Bio Inc. (NUVB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nuvation Bio Inc. NUVB $2.39B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Nuvation Bio Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Visit website →